Shell Asset Management CO Hutchmed (China) LTD Transaction History

Shell Asset Management CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$8.59 - $20.77 $81,605 - $197,315	-9,500 Reduced 53.01%	8,420 $106,000
Q3 2020 Nov 13, 2020	BUY	$25.8 - $34.61 $95,795 - $128,506	3,713 Added 26.14%	17,920 $579,000
Q2 2020 Aug 10, 2020	BUY	$17.65 - $28.05 $91,779 - $145,860	5,200 Added 57.73%	14,207 $392,000
Q1 2020 May 11, 2020	BUY	$15.19 - $29.51 $65,317 - $126,893	4,300 Added 91.35%	9,007 $161,000
Q4 2019 Feb 13, 2020	SELL	$17.17 - $25.95 $387,509 - $585,665	-22,569 Reduced 82.74%	4,707 $118,000
Q3 2019 Nov 12, 2019	SELL	$17.84 - $22.69 $52,378 - $66,617	-2,936 Reduced 9.72%	27,276 $487,000
Q2 2019 Aug 12, 2019	SELL	$22.0 - $31.78 $335,192 - $484,200	-15,236 Reduced 33.52%	30,212 $665,000
Q4 2018 Feb 13, 2019	BUY	$23.09 - $37.69 $1.05 Million - $1.71 Million	45,448 New	45,448 $1.05 Million

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.9B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.